NEW YORK, April 23, 2015 /PRNewswire/ -- Anavex Life Science Corp. (OTCMKTS: AVXL) was incorporated on January 23, 2004. The company's lead compounds include ANAVEX 2-73, ANAVEX PLUS, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer's disease and other central nervous system diseases.
The Company closed on April 22nd at a price of $0.45, recording a gain of 1.12% with a Volume of 3.44M. Recent stock appreciation has initiated this analyst brief report.
For a closer look at Anavex Life Science and analyst insights please follow the link below. There is no cost obligation to view this report.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by Olubusayo Faderin, research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.